Inicio・Lista de Acciones・Alkermes PLC

Alkermes PLC

Cerrado

SectorSanidad

52.36 0.02

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

51.15

Máximo

53.02

Métricas clave
By Trading Economics
Ingresos	-116M -66M
Ventas	8.4M 393M
P/B Media del Sector	58.773 62.58
BPA	0.38
Margen de beneficios	-16.92
Empleados	2,050
EBITDA	-98M -22M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+6.05% upside

Dividendos
By Acuity
Próximas Ganancias	28 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.9B 8.6B
Apertura anterior	52.34
Cierre anterior	52.36

Noticias sobre sentimiento de mercado

By Acuity

10%

90%

6 / 340 Clasificación en Healthcare

Alkermes PLC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 18:46 UTC

Alkermes shares are higher today, supported by improved market sentiment and renewed interest in AI stocks. The asset is trading near its one-month range high.

20 jul 2026, 22:01 UTC

Alkermes Plc shares declined after-market, retracing from earlier peaks. The asset is currently below its 20-day moving average.

Comparación entre iguales

Cambio de precio

Alkermes PLC previsión

Precio Objetivo

By TipRanks

6.05% repunte

Estimación a 12 Meses

Media 54.85 USD 6.05%

Máximo 65 USD

Mínimo 38 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Alkermes PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

13 ratings

Comprar

Mantener

Vender

De acuerdo con 13 analistas que ofrecen calificaciones bursátiles a para Alkermes PLC Dist en los últimos 3 meses.

Sentimiento

By Acuity

6 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.